A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial c...
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
PD1 inhibition is effective in patients with metastatic urothelial cancer (mUC), yet a large fraction of patients does not respond. In this study, we aimed to identify a blood-based immune marker associated with non-response to facilitate patient selection for anti-PD1. To this end, we quantified 18 immune cell populations using multiplex flow cyto...
Alternative Titles
Full title
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9947015
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9947015
Other Identifiers
ISSN
0340-7004
E-ISSN
1432-0851
DOI
10.1007/s00262-022-03250-0
